Emmaus Life Sciences, Inc. (EMMA)
EMMA is quoted over the counter, not listed on an exchange. Emmaus Life Sciences, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | EMMA, quoted over the counter |
| SEC CIK | 0000822370 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Torrance, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Because the Company's existing cash balance and anticipated cash flows cannot satisfy its current debt and ongoing obligations, combined with the uncommitted nature of the Company's financing plans, there is substantial doubt about the Company's ability to continue as a going concern for 12 months from the date that these condensed consolidated financial statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $2.8M cash; operating cash flow $992K a quarter. | Report 2026-06-30 |
| Shares outstanding | 70,188,263 (2026-08-11); 63,865,571 a year earlier; 53,637,554 three years earlier. | Cover page 2026-08-11 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $15K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $6.3M | $1.3M | $1.7M | $2.8M | $25.0M | $15.5M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $2.0M | -$3.3M | -$344K | $1.1M | $26.6M | $12.0M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $3.9M | -$2.0M | $2.2M | $2.1M | $27.1M | $12.5M | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $3.4M | -$2.1M | $409K | $293K | $29.1M | $11.9M | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $2.8M | -$1.1M | -$2.9M | $886K | $29.7M | $14.0M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $2.4M | -$2.3M | $279K | $1.3M | $29.0M | $16.6M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $3.3M | -$1.7M | $343K | $1.4M | $29.0M | $16.7M | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | $5.5M | $1.8M | $148K | $1.3M | $29.3M | $20.4M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2020-03-03 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-08-14 |
| Latest proxy | DEF 14A | 2022-10-31 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier